title: Intravitreal PRN ranibizumab treatment for macular edemadue to branch retinal vein occlusion.
abstract: To evaluate the effect of intravitreal pro re nata (PRN) ranibizumab treatment from the start on the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) in macular edema (ME) due to branch retinal vein occlusion (BRVO).
  
  
  
  Patients with ME secondary to BRVO, who were treated on a PRN basis after a single intravitreal ranibizumab injection, were retrospectively evaluated. The main outcome measures were changes in BCVA and CRT as measured by optical coherence tomography.
  
  
  
  The number of injections over 6 months was 2.43 ± 1.16. The mean BCVA of the patients was 0.84 ± 0.10 logMAR at baseline and 0.41 ± 0.06 at the 6th month (P < 0.001). Mean BCVA of the ischemic BRVO group was 1.06 ± 0.68 logMAR at baseline and 0.44 ± 0.30 logMAR at the 6th month (P < 0.05). Similarly, the mean BCVA of the nonischemic BRVO group was 0.77 ± 0.53 logMAR at baseline and 0.41 ± 0.36 logMAR at the 6th month (P < 0.05). Between groups, there was no significant difference in mean BCVA at any examination.
  
  
  
  Intravitreal ranibizumab is a safe and effective treatment option for ME due to ischemic and nonischemic BRVO using PRN from the start.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
authors.forename: Hasan Basri
authors.initials: HB
authors.lastname: Çakmak
authors.affiliation: Department of Ophthalmology, Ankara Atatürk Education and Research Hospital, Ankara, Turkey.
authors.forename: Mücella
authors.initials: M
authors.lastname: Arikan Yorgun
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
authors.forename: Yasin
authors.initials: Y
authors.lastname: Toklu
authors.affiliation: Department of Ophthalmology, Ankara Atatürk Education and Research Hospital, Ankara, Turkey.
authors.forename: Melek
authors.initials: M
authors.lastname: Mutlu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D012170:Retinal Vein Occlusion / Q000150:complications*; D012189:Retrospective Studies; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab